Author Description

Presents an extensively referenced, evidence-based analysis of the role of imaging in planning treatment. Emphasizing image interpretation for tumor staging and follow-up, the editors and their panel of chapter authors explore the advantages and limitations of all relevant imaging modalities including ultrasound, CT, MRI, PET/CT, and other nuclear medicine techniques. New material includes expanded chapters on all the common tumors and new data on the late development of second malignancies following successful therapy. New chapters in the text reflect the ever widening application of imaging to different cancers such as adrenal tumors, neuroendocrine tumors, splenic malignancy, and malignant melanoma metastases. The expanded section on imaging the immunocompromised host contains new chapters on general clinical considerations and on imaging the central nervous system. All chapters have been revised, many of the images have been replaced with state-of-the-art imaging on multi-channel CT and MR, and positron tomography has been introduced into the text where relevant. Although they include a section on new horizons in cancer imaging, such as the imaging of angiogenesis, MR lymphography, and the rapidly evolving field of molecular imaging, the editors have not neglected the more traditional general principles of cancer behavior and imaging. They discuss assessment of response, the effect of treatment on normal tissues, the complications of treatment, and the risk of second malignancies, issues that become important as therapy becomes more successful.